ImmunityBio’s (IBRX) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a $23.00 target price on the stock.

Other analysts have also recently issued reports about the stock. Piper Sandler reiterated an “overweight” rating and issued a $12.00 target price (up from $7.00) on shares of ImmunityBio in a research note on Wednesday, March 4th. Weiss Ratings reiterated a “sell (e+)” rating on shares of ImmunityBio in a research note on Monday, December 29th. HC Wainwright lifted their target price on shares of ImmunityBio from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, February 23rd. The Goldman Sachs Group reiterated a “buy” rating on shares of ImmunityBio in a research note on Monday, February 23rd. Finally, Jefferies Financial Group boosted their price objective on shares of ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $14.40.

ImmunityBio Stock Up 1.7%

NASDAQ IBRX opened at $6.98 on Wednesday. The stock has a market capitalization of $7.18 billion, a PE ratio of -18.37 and a beta of 0.13. The company has a 50 day moving average price of $7.80 and a two-hundred day moving average price of $4.48. ImmunityBio has a 12-month low of $1.83 and a 12-month high of $12.43.

ImmunityBio (NASDAQ:IBRX) last posted its earnings results on Monday, February 23rd. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The business had revenue of $38.29 million during the quarter. As a group, equities analysts anticipate that ImmunityBio will post -0.92 EPS for the current year.

Insiders Place Their Bets

In other news, Director Christobel Selecky sold 25,000 shares of the business’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $10.00, for a total value of $250,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Barry J. Simon sold 75,000 shares of the business’s stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $12.01, for a total transaction of $900,750.00. Following the completion of the sale, the director owned 2,850,821 shares of the company’s stock, valued at $34,238,360.21. The trade was a 2.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 501,967 shares of company stock valued at $4,466,412 over the last 90 days. 69.48% of the stock is owned by corporate insiders.

Institutional Trading of ImmunityBio

Institutional investors and hedge funds have recently modified their holdings of the company. Slow Capital Inc. acquired a new position in ImmunityBio during the 3rd quarter valued at $25,000. Truist Financial Corp acquired a new position in ImmunityBio during the 3rd quarter valued at $27,000. Swiss Life Asset Management Ltd acquired a new position in ImmunityBio during the 3rd quarter valued at $27,000. WealthPlan Investment Management LLC acquired a new position in ImmunityBio during the 4th quarter valued at $27,000. Finally, Diversify Advisory Services LLC acquired a new position in ImmunityBio during the 2nd quarter valued at $27,000. 8.58% of the stock is currently owned by institutional investors and hedge funds.

ImmunityBio News Roundup

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: D. Boral Capital reaffirmed a “buy” rating and set a $23 price target on IBRX, implying large upside versus the current price; this analyst backing can support investor confidence and buying interest. Benzinga
• Neutral Sentiment: Coverage and news items note renewed attention on Anktiva ahead of potential data linking COVID history and cancer outcomes — this could re-focus the market on clinical opportunity, but is speculative until data are reported. MSN
• Neutral Sentiment: ImmunityBio issued a response to the FDA warning outlining intended compliance fixes while stressing ongoing sales growth and business expansion; the company’s remediation steps may limit further regulatory damage but do not remove current uncertainty. Zacks
• Negative Sentiment: Numerous law firms have filed or are soliciting lead-plaintiff applicants in a securities class action (class period Jan. 19–Mar. 24, 2026) alleging misleading statements about Anktiva after an FDA warning; collective notice campaigns and potential litigation exposure increase legal risk and already pressured the stock earlier. Business Wire
• Negative Sentiment: Multiple press releases from plaintiff firms and legal notices (Hagens Berman, KSF, Pomerantz, Rosen, et al.) emphasize the FDA warning and note a significant prior share-price drop; continued legal publicity and potential settlement/defense costs are a downside risk for holders. PR Newswire (Hagens Berman)

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.